Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.26

-0.34 (-0.26%)

14:23
07/17/17
07/17
14:23
07/17/17
14:23

On The Fly: What to watch in Johnson & Johnson earnings report

Johnson & Johnson (JNJ) is scheduled to report results of its fourth fiscal quarter before the market open on July 18, with a conference call scheduled for 8:30 am EDT. What to watch for: 1. UPBEAT GUIDANCE: Along with its last report, J&J raised its fiscal year 2017 earnings per share view to $7.00-$7.15 from S $6.93-$7.08, versus a consensus at the time of $7.05. Analysts currently see the company reporting EPS of $7.10 this fiscal year. On April 19, the day after J&J's Q1 earnings release, research firm UBS said that the company's quarterly EPS results were a "solid" beat. The firm raised its estimates to reflect the Actelion (ALIOF), deal which is expected to close in Q2. UBS reiterated its Buy rating and $136 price target on Johnson & Johnson shares. Another research firm, Leerink, weighed in on J&J earnings after its last report. Leerink analyst Danielle Antalffy lowered her price target for Johnson & Johnson to $140 from $150 on valuation. The analyst noted that the shares sold off as investors seemed taken aback by weakness in both non-REMICADE Pharma and Consumer, but she pointed out that there were a number of potential drivers for an improving outlook going forward, including Medical Devices growth reacceleration, continued strong double-digit growth of key new drugs, and likely consumer growth reacceleration as the macroeconomic environment improves. The analyst reiterated an Outperform rating on the shares. 2. TOUGH PHARMA ENVIRONMENT: According to a research paper from University of Pennsylvania, out in May, the pharmaceutical industry faces some critical challenges, including the decline in the discovery, approval and marketing of new chemical entities with fewer and fewer blockbuster drugs making it to the market, competition from generics drugs, regulatory pressures and the weak growth in the U.S. market and therefore the need to explore other markets, to name a few. Recently, JPMorgan analyst Michael Weinstein noted the difficult conditions for pharma and their potential impact on J&J's Q2 results." J&J is coming off a disappointing Q1, and Q2 is going to be just as challenging, owing to $340M in Q2 of 2016 gross-to-net adjustments that make for a particularly tough comp. As a result, Q2 is likely to look a lot like the first," wrote Weinstein in a note out in early May. JP Morgan analyst Weinstein and his team called attention to the fact that J&J shares underperformed due to "the prospect of decelerating top-line growth in 2017, owing to increased competition for the Pharmaceutical business. According to JP Morgan's Weinstein deceleration should abate after the current quarter, which him to raise his rating to Overweight and price target to $140 on J&J shares. ACTELION ACQUISITION: In late January, J&J announced it was acquiring Switzerland-based Actelion. Actelion has a "strong" history of innovation to discover and develop new and differentiated products in multiple therapeutic areas, J&J said in a press release on January 26. Actelion has developed oral, inhaled and intravenous formulations of compounds to treat patients at various stages of pulmonary arterial hypertension. It is also developing therapies for multiple sclerosis, digital ulcers, Niemann-Pick type C disease, Gaucher disease, a lymphoma known as mycosis fungoides, and infectious diseases such as Clostridium difficile-associated diarrhea. The transaction closed on June 16 and will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson expects the transaction to add approximately $1.3B in sales for 2017 and be accretive to 2017 adjusted EPS by approximately 7c. This impact was already included in the company's full-year sales and adjusted EPS guidance provided in April. Also, as previously disclosed, in the first full year after close, Johnson & Johnson expects the transaction to be accretive to adjusted EPS by 35c-40c.

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$132.26

-0.34 (-0.26%)

07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

CTL

CenturyLink

$23.37

0.15 (0.65%)

12:35
07/22/17
07/22
12:35
07/22/17
12:35
Periodicals
CenturyLink CEO disagrees with Minnesota Attorney General claims, Reuters says »

CenturyLink CEO Glen Post…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

DB

Deutsche Bank

$18.22

-0.24 (-1.30%)

, JPM

JPMorgan

$90.89

-0.31 (-0.34%)

12:30
07/22/17
07/22
12:30
07/22/17
12:30
Periodicals
Deutsche Bank, JPMorgan to pay $148M to end yen Libor litigation, Reuters says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$18.22

-0.24 (-1.30%)

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

C

Citi

$66.00

-0.36 (-0.54%)

HSBC

HSBC

$47.86

-0.25 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

, BMWYY

BMW

$31.52

-0.73 (-2.26%)

12:20
07/22/17
07/22
12:20
07/22/17
12:20
Periodicals
EU regulators investigating German car cartel allegations, Reuters reports »

EU antitrust regulators…

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

BMWYY

BMW

$31.52

-0.73 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

12:11
07/22/17
07/22
12:11
07/22/17
12:11
Periodicals
Seat chief sees CNG as an alternative to diesel, Reuters reports »

Seat, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$109.31

-0.53 (-0.48%)

12:03
07/22/17
07/22
12:03
07/22/17
12:03
Periodicals
Toyota to begin mass EV production in China as early as 2019, Reuters says »

Toyota Motor is likely to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$212.14

1.86 (0.88%)

, EADSY

Airbus

$20.89

-0.08 (-0.38%)

11:57
07/22/17
07/22
11:57
07/22/17
11:57
Periodicals
Boeing looking to rely on more factory automation, WSJ reports »

Boeing (BA) is cutting…

BA

Boeing

$212.14

1.86 (0.88%)

EADSY

Airbus

$20.89

-0.08 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

PUGOY

Peugeot

$21.51

-0.716 (-3.22%)

, GM

General Motors

$36.07

-0.34 (-0.93%)

11:50
07/22/17
07/22
11:50
07/22/17
11:50
Periodicals
Open defends employee leases inclusion in sales figures, Reuters reports »

Opel, which is being…

PUGOY

Peugeot

$21.51

-0.716 (-3.22%)

GM

General Motors

$36.07

-0.34 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FB

Facebook

$164.43

-0.1 (-0.06%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

11:39
07/22/17
07/22
11:39
07/22/17
11:39
Periodicals
Facebook, Apple troubles in China no longer a surprise, NY Times says »

Facebook (FB), Apple…

FB

Facebook

$164.43

-0.1 (-0.06%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

MSFT

Microsoft

$73.79

-0.43 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

  • 05

    Sep

  • 13

    Sep

WFC

Wells Fargo

$54.17

-0.71 (-1.29%)

10:14
07/22/17
07/22
10:14
07/22/17
10:14
Periodicals
Wells Fargo investigating information sent to attorney, Bloomberg reports »

Wells Fargo said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 15

    Jan

COKE

Coca-Cola Bottling

$240.86

-0.94 (-0.39%)

09:51
07/22/17
07/22
09:51
07/22/17
09:51
Hot Stocks
Coca-Cola Bottling announces 25c dividend for third quarter »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:41
07/22/17
07/22
09:41
07/22/17
09:41
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:40
07/22/17
07/22
09:40
07/22/17
09:40
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DF

Dean Foods

$15.35

-0.02 (-0.13%)

09:33
07/22/17
07/22
09:33
07/22/17
09:33
Periodicals
Cheddar prices could rise further, Barron's says »

Prices for block cheddar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

, FDX

FedEx

$212.51

0.63 (0.30%)

09:25
07/22/17
07/22
09:25
07/22/17
09:25
Periodicals
Issuing debt to fund pensions 'not cause for worry,' Barron's says »

Issuing debt to fund…

KR

Kroger

FDX

FedEx

$212.51

0.63 (0.30%)

DAL

Delta Air Lines

$52.26

-0.57 (-1.08%)

DD

DuPont

$84.54

-0.29 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SRPT

Sarepta

$43.41

2.48 (6.06%)

09:14
07/22/17
07/22
09:14
07/22/17
09:14
Periodicals
Upbeat sales news, guidance boost lift Sarepta shares, Barron's reports »

Sarepta's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, SHLD

Sears

$8.83

-0.77 (-8.02%)

09:09
07/22/17
07/22
09:09
07/22/17
09:09
Periodicals
Nothing is 'Amazon-proof,' Barron's says »

Amazon's (AMZN) deal…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

SHLD

Sears

$8.83

-0.77 (-8.02%)

HD

Home Depot

$146.65

-0.38 (-0.26%)

LOW

Lowe's

$73.84

1.28 (1.76%)

BBY

Best Buy

$54.14

0.18 (0.33%)

M

Macy's

$23.36

0.29 (1.26%)

KSS

Kohl's

$40.46

0.47 (1.18%)

ORLY

O'Reilly Automotive

$188.19

-0.5 (-0.26%)

AAP

Advance Auto Parts

$105.27

2.04 (1.98%)

WFM

Whole Foods

$41.71

-0.05 (-0.12%)

KR

Kroger

COST

Costco

$150.44

-0.55 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 27

    Jul

  • 15

    Aug

  • 23

    Aug

  • 29

    Aug

BA

Boeing

$212.14

1.86 (0.88%)

, LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

08:58
07/22/17
07/22
08:58
07/22/17
08:58
Periodicals
Aviation, defense stocks have 'juicy yields,' Barron's says »

Some aerospace and…

BA

Boeing

$212.14

1.86 (0.88%)

LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

UTX

United Technologies

$123.49

1.04 (0.85%)

RTN

Raytheon

$169.37

0.59 (0.35%)

LLL

L3 Technologies

$176.62

-1.1 (-0.62%)

GD

General Dynamics

$204.55

2.15 (1.06%)

NOC

Northrop Grumman

$265.30

0.53 (0.20%)

COL

Rockwell Collins

$109.31

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 15

    Aug

  • 23

    Aug

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

08:50
07/22/17
07/22
08:50
07/22/17
08:50
Periodicals
Amazon, others could be threat to fiberoptic markers, Barron's says »

Amazon.com (AMZN),…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

GOOG

Alphabet

$972.92

4.77 (0.49%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

FB

Facebook

$164.43

-0.1 (-0.06%)

AAOI

Applied Optoelectronics

$89.95

1.15 (1.30%)

LITE

Lumentum

$63.35

2.9 (4.80%)

OCLR

Oclaro

$9.90

0.04 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 05

    Sep

  • 13

    Sep

  • 13

    Sep

NKE

Nike

$59.95

0.85 (1.44%)

, FB

Facebook

$164.43

-0.1 (-0.06%)

08:28
07/22/17
07/22
08:28
07/22/17
08:28
Periodicals
AllianceBernstein's Caruso sees EPS as 'poor' report card, Barron's says »

Frank Caruso, the chief…

NKE

Nike

$59.95

0.85 (1.44%)

FB

Facebook

$164.43

-0.1 (-0.06%)

ISRG

Intuitive Surgical

$927.47

-44.26 (-4.55%)

ANET

Arista Networks

$152.92

-3.88 (-2.47%)

AB

AllianceBernstein

$24.75

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

  • 16

    Aug

  • 17

    Aug

  • 21

    Aug

  • 13

    Sep

FLEX

Flex

$16.74

-0.07 (-0.42%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

07:53
07/22/17
07/22
07:53
07/22/17
07:53
Periodicals
Flex could rise 25% in a year, Barron's says »

Flex (FLEX) is using…

FLEX

Flex

$16.74

-0.07 (-0.42%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

LNVGY

Lenovo

$12.63

0.18 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

LUK

Leucadia

$26.45

0.03 (0.11%)

07:46
07/22/17
07/22
07:46
07/22/17
07:46
Periodicals
Leucadia shareholders to 'finally' see reward, Barron's says »

Five years after Leucadia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

07:39
07/22/17
07/22
07:39
07/22/17
07:39
Periodicals
Morgan Stanley CEO would not kill off Dodd-Frank, Barron's reports »

Morgan Stanley CEO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

, JPM

JPMorgan

$90.89

-0.31 (-0.34%)

07:34
07/22/17
07/22
07:34
07/22/17
07:34
Periodicals
Big bank profits could be lifted 30% by deregulation, Barron's says »

While a major overhaul is…

MS

Morgan Stanley

$46.59

0.08 (0.17%)

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

GS

Goldman Sachs

$220.18

-2.12 (-0.95%)

C

Citi

$66.00

-0.36 (-0.54%)

STT

State Street

$90.99

0.12 (0.13%)

BK

BNY Mellon

$53.36

-0.55 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 01

    Aug

  • 12

    Oct

  • 17

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BCC

Boise Cascade

$29.35

0.4 (1.38%)

, CAT

Caterpillar

$106.59

-0.73 (-0.68%)

07:19
07/22/17
07/22
07:19
07/22/17
07:19
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

BCC

Boise Cascade

$29.35

0.4 (1.38%)

CAT

Caterpillar

$106.59

-0.73 (-0.68%)

CPB

Campbell Soup

$52.00

0.08 (0.15%)

LVB

Steinway Musical

GLW

Corning

$31.85

0.14 (0.44%)

MRK

Merck

$62.63

-0.31 (-0.49%)

PFE

Pfizer

$33.48

-0.06 (-0.18%)

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

AET

Aetna

$156.31

0.58 (0.37%)

ANTM

Anthem

$190.65

-0.04 (-0.02%)

CNC

Centene

$84.73

-0.67 (-0.78%)

CI

Cigna

$174.23

-0.26 (-0.15%)

HNT

Health Net

HUM

Humana

$235.92

0.09 (0.04%)

MOH

Molina Healthcare

$71.15

-0.9 (-1.25%)

UNH

UnitedHealth

$191.78

0.28 (0.15%)

WCG

WellCare

$183.87

0.1 (0.05%)

X

U.S. Steel

$23.68

-0.47 (-1.95%)

STLD

Steel Dynamics

$37.51

-0.18 (-0.48%)

NUE

Nucor

$60.23

0.31 (0.52%)

CYH

Community Health

$9.27

0.01 (0.11%)

HCA

HCA Holdings

$85.73

-0.03 (-0.03%)

LPNT

LifePoint

$65.35

-0.15 (-0.23%)

THC

Tenet

$20.65

-0.02 (-0.10%)

UHS

Universal Health

$124.42

-0.58 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 30

    Jul

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 04

    Aug

  • 04

    Aug

  • 08

    Aug

  • 14

    Aug

  • 23

    Aug

  • 27

    Aug

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

MET

MetLife

$54.65

0.07 (0.13%)

18:20
07/21/17
07/21
18:20
07/21/17
18:20
Periodicals
U.S. regulators to go over MetLife suit at July 28 meeting, Reuters says »

Leaders at the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 14

    Aug

  • 15

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.